$527 million dollars! Kai Pharmaceuticals (02105) hits the gold target, joining NewCo 2.0.

The BD is no longer fresh, but if it gets a 50% profit sharing, this will be a super large deal. On the morning of June 10th, Lai Kai Medicine (02105) announced a collaboration with Vasque Bio on LAE118 (a new PI3K pan-mutant selective inhibitor), with a total upfront payment and milestone payment of up to $527 million, a gradient sales sharing percentage ranging from single digits to double digits, and the right to receive up to a high double-digit percentage of the issued common stock of Vasque Bio or a cash payment in place of such common stock. If Vasque Bio engages in future strategic partnerships or acquisitions related to LAE118, Lai Kai has the right to receive additional profit sharing payments, up to 50% of the value of the strategic transaction. Why is PI3K considered a golden target? The PI3K/AKT/mTOR signaling pathway is the master switch of cellular metabolism, and PIK3CA gene mutation is one of the most frequent genetic changes in human cancers, attracting intense competition. Companies like Lilly and Novartis have acquired new generation PI3K inhibitors for $2.5 billion and $3 billion, respectively. Lai Kai's LAE118 is a new generation PI3K inhibitor with blockbuster potential, offering higher efficacy and a wider safety window. Why is this collaboration seen as locking in a super large deal? The focus of Chinese innovative drug outward BD is shifting towards late-stage monetization and overseas equity distribution ratios. Connoa's CM336 (BCMAxCD3 bispecific) was traded overseas in 2024, with only $16 million upfront payment, but the company was later acquired by Gilead for $2.175 billion, earning $257 million in upfront payment. Lai Kai's LAE118 has an initial payment of $10 million for overseas market entry, but if Vasque Bio is acquired, Lai Kai could receive up to a 50% profit-sharing percentage. The complementary experience of both teams has led to the synergy of oncology + VM (vascular malformation)/rare diseases in this collaboration, accelerating the realization of the maximum value of LAE118 and expanding its global value. The key is Vasque Bio's TCG, known as the king of monetization, which has a high success rate in exiting the biotech industry, with a swift turnaround. TCG has a mature model of rapid monetization, with BD agreements reached within 6-12 months and acquisition exits within 18-24 months. The example of Relay Therapeutics in May 2026 showcases the market potential of the new PI3K inhibitor Zovegalisib, estimating a total market size of approximately $15-19 billion. Notably, Zovegalisib demonstrates impressive therapeutic value in PIK3C-driven vascular anomalies (VAs) patients, with lesion volume relief rates reaching 60% in various dose groups. The rarity of PI3K inhibitors has MNCs scrambling for scarce targets. Lilly's acquisition of STX-478 for $2.5 billion in 2025, and Novartis's acquisition of SNV4818 for $3 billion in March, have solidified their positions in HR-positive breast cancer. Lai Kai's LAE118 has the potential to be a blockbuster among the new generation of PI3K inhibitors. LAE118 is anticipated to have a strong competitive edge as a new pan-mutant selective PI3K inhibitor, showing excellent in vitro anti-proliferative activity in PI3K mutant cell lines and remaining effective in cells resistant to conventional PI3K inhibitors. With a lower impact on blood glucose and insulin compared to other inhibitors, as demonstrated in preclinical toxicology studies, LAE118 has a higher efficacy and broader safety margin. Finally, the author highlights the shift towards long-term revenue sharing and equity distribution in collaborations like this one, emphasizing the importance of strategic partnerships in the biotech industry's future.